search
Back to results

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

Primary Purpose

Leukemia

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
AEG35156
Sponsored by
Aegera Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring Acute, myeloid, leukemia, antisense, chemotherapy, idarubicin, cytarabine, Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen.

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen. The diagnosis of refractory AML is based on the presence of either > 10% blasts in marrow or blood or 5-10% blasts in either site together with cytopenia (Hb < 10 g/dL, or platelets < 100 x 109/L, or neutrophil count < 1.0 x 109/L).
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
  • Male, or female patients who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile.
  • Patients must have adequate organ and immune function as indicated by the following laboratory values:

Parameter Laboratory Values Serum creatinine; ≤2.0 mg/dL (≤ 177 μmol/L Total Bilirubin ≤2.0 mg/dL (≤ 34 μmol/L) AST (SGOT) and ALT (SGPT) ≤3 X ULN

  • The patient must understand, be able and willing and likely to fully comply with study procedures, including scheduled follow-up, and restrictions.

Exclusion Criteria:

  • Clinical evidence of ongoing grade 3 or 4 non-hematological toxicities from the initial standard dose cytarabine-based induction chemotherapy
  • Patients with a prior history of peripheral neuropathy of grade 2 or higher.
  • Clinical evidence of active CNS leukemic involvement.
  • Active and uncontrolled infection. Patients with an infection who are under active treatment with antibiotics and whose infections are controlled may be entered to the study.
  • Current evidence of invasive fungal infection (blood or tissue culture).
  • Current evidence of an active second malignancy except for non-melanoma skin cancer.
  • Uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair a patient's ability to give informed consent or unacceptably reduce the safety of the proposed treatment.
  • Neurological or psychiatric disorders that would interfere with consent or study follow-up.
  • Known or suspected intolerance or hypersensitivity to the study drugs [or closely related compounds] or any of their stated ingredients. Study drugs being the antisense, cytarabine and idarubicin.
  • History of alcohol or other substance abuse within the last year.
  • Use of another investigational agent within the last 14 days prior to enrolment. Patients who have received a previous antisense agent in the last 90 days will be excluded.
  • Female patients who are pregnant, lactating, or with a positive pregnancy test at screening must be excluded.

Sites / Locations

  • UCLA School of Medicine
  • Rocky Mountain Blood & Marrow Transplant Program
  • Northwestern University Med School, div. Oncology & Hematology
  • New York Medical College
  • MD Anderson Cancer Center University of Texas
  • Cancer Research Institute of Scott & White Hospital
  • Princess Margaret Hospital
  • Hopital Charles Lemoyne
  • Hopital Maisonneuve-Rosemont
  • Hopital Sacre Coeur
  • Klinikum Chemnitz gGmbH
  • St. Johannes Hospital
  • Universitatsklinimum Essen
  • Universitatsklinikum Hamburg-Eppendorf
  • 2. Medizinische Klinik und Poliklinik im Stadtischen Krankenhaus Kile GmgH
  • III. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universitat
  • Medizinische Klinik a Hamatologie und Onkologie
  • Robert Boasch Krankenhaus Stuttgart

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

AEG35156

Control

Arm Description

Patient receive AEG35156 prior to chemotherapy

Patients receive chemotherapy only

Outcomes

Primary Outcome Measures

To determine if AEG35156 can enhance the CR and CR with incomplete platelet recovery (CRp) rate and duration of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.

Secondary Outcome Measures

To determine if AEG35156 can enhance overall survival, is safe and measured (Pharmacokinetic) following high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.

Full Information

First Posted
November 19, 2009
Last Updated
July 12, 2011
Sponsor
Aegera Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT01018069
Brief Title
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Official Title
An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
Study Type
Interventional

2. Study Status

Record Verification Date
July 2011
Overall Recruitment Status
Terminated
Why Stopped
Failed to reach endpoints
Study Start Date
November 2009 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Aegera Therapeutics

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
Acute, myeloid, leukemia, antisense, chemotherapy, idarubicin, cytarabine, Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen.

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AEG35156
Arm Type
Active Comparator
Arm Description
Patient receive AEG35156 prior to chemotherapy
Arm Title
Control
Arm Type
Sham Comparator
Arm Description
Patients receive chemotherapy only
Intervention Type
Drug
Intervention Name(s)
AEG35156
Intervention Description
2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
Primary Outcome Measure Information:
Title
To determine if AEG35156 can enhance the CR and CR with incomplete platelet recovery (CRp) rate and duration of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
To determine if AEG35156 can enhance overall survival, is safe and measured (Pharmacokinetic) following high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based frontline induction regimen.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with AML, except those with APL (acute promyelocytic leukemia), failing a single standard dose cytarabine based frontline induction regimen. The diagnosis of refractory AML is based on the presence of either > 10% blasts in marrow or blood or 5-10% blasts in either site together with cytopenia (Hb < 10 g/dL, or platelets < 100 x 109/L, or neutrophil count < 1.0 x 109/L). Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. Male, or female patients who are post-menopausal (amenorrheic for at least 12 months), or surgically or biologically sterile. Patients must have adequate organ and immune function as indicated by the following laboratory values: Parameter Laboratory Values Serum creatinine; ≤2.0 mg/dL (≤ 177 μmol/L Total Bilirubin ≤2.0 mg/dL (≤ 34 μmol/L) AST (SGOT) and ALT (SGPT) ≤3 X ULN The patient must understand, be able and willing and likely to fully comply with study procedures, including scheduled follow-up, and restrictions. Exclusion Criteria: Clinical evidence of ongoing grade 3 or 4 non-hematological toxicities from the initial standard dose cytarabine-based induction chemotherapy Patients with a prior history of peripheral neuropathy of grade 2 or higher. Clinical evidence of active CNS leukemic involvement. Active and uncontrolled infection. Patients with an infection who are under active treatment with antibiotics and whose infections are controlled may be entered to the study. Current evidence of invasive fungal infection (blood or tissue culture). Current evidence of an active second malignancy except for non-melanoma skin cancer. Uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair a patient's ability to give informed consent or unacceptably reduce the safety of the proposed treatment. Neurological or psychiatric disorders that would interfere with consent or study follow-up. Known or suspected intolerance or hypersensitivity to the study drugs [or closely related compounds] or any of their stated ingredients. Study drugs being the antisense, cytarabine and idarubicin. History of alcohol or other substance abuse within the last year. Use of another investigational agent within the last 14 days prior to enrolment. Patients who have received a previous antisense agent in the last 90 days will be excluded. Female patients who are pregnant, lactating, or with a positive pregnancy test at screening must be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aaron Schimmer, MD
Organizational Affiliation
Princess Margaret Hospital, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA School of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Rocky Mountain Blood & Marrow Transplant Program
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Facility Name
Northwestern University Med School, div. Oncology & Hematology
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
New York Medical College
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Facility Name
MD Anderson Cancer Center University of Texas
City
Houston
State/Province
Texas
ZIP/Postal Code
77303
Country
United States
Facility Name
Cancer Research Institute of Scott & White Hospital
City
Temple
State/Province
Texas
ZIP/Postal Code
76502
Country
United States
Facility Name
Princess Margaret Hospital
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Hopital Charles Lemoyne
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2H1
Country
Canada
Facility Name
Hopital Maisonneuve-Rosemont
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Hopital Sacre Coeur
City
Montreal
State/Province
Quebec
Country
Canada
Facility Name
Klinikum Chemnitz gGmbH
City
Chemnitz
ZIP/Postal Code
09113
Country
Germany
Facility Name
St. Johannes Hospital
City
Duisburg
ZIP/Postal Code
47166
Country
Germany
Facility Name
Universitatsklinimum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Universitatsklinikum Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
2. Medizinische Klinik und Poliklinik im Stadtischen Krankenhaus Kile GmgH
City
Kiel
ZIP/Postal Code
24116
Country
Germany
Facility Name
III. Medizinische Klinik und Poliklinik der Johannes Gutenberg-Universitat
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Medizinische Klinik a Hamatologie und Onkologie
City
Munster
ZIP/Postal Code
48129
Country
Germany
Facility Name
Robert Boasch Krankenhaus Stuttgart
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen

We'll reach out to this number within 24 hrs